Michael Panny - 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 34 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Advanced Stage Hodgkinʼs Lymphoma 2024—update on First Line Treatment

Barbara Lehner,Michael Panny

memo - Magazine of European Medical Oncologypp.1-3, (2024)

引用0浏览0引用

Aggressive B Cell Lymphomas—highlights from ASH 2022

Michael Panny

memo - Magazine of European Medical Oncologyno. 3 (2023): 149-151

引用1浏览0引用

Comorbidity & cll different scores – different results

V. Rathkolb,Thomas Nösslinger, M. Gittenberger,Michael Panny,Ernst Forjan,Elisabeth Menschel,Ralph Simanek, Karin Fleiß,Anabel Schönmetzler, Bahner Alexandra, K. Theresia,Elisabeth Koller,

Hematological Oncologyno. S2 (2023): 732-732

引用0浏览0引用

Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth,Tea Pemovska,Gregory I. Vladimer,Günther Bayer, Michael Bergmann,Sandra Eder,Ruth Eichner, Martin Erl,Harald Esterbauer,Ruth Exner,Verena Felsleitner-Hauer,Maurizio Forte,

crossref（2023）

引用0浏览0引用

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NH..

Thomas Melchardt, Rebecca I. Wurm-Kuczera,Bettina Altmann,Petra Pichler, Manuel Orlinger,Michael Panny,Luisa Wohn,Andreas Rosenwald,Dirk Hellwig,Sascha Dietrich,Bertram Glass,Georg Lenz,

Bloodno. Supplement 1 (2023): 1734-1734

引用0浏览0引用

BendaEAM Versus BEAM As Conditioning Regimen for ASCT in Patients with Relapsed Lymphoma (BEB): a Multicentre, Randomised, Phase 2 Trial

Felix Keil,Antonia M. S. Mueller,Andrea Berghold,Regina Riedl,Veronika Buxhofer-Ausch,Judith Schuster,Corinne Vorburger,Alexandra Boehm,Michael Panny,Thomas Noesslinger,Richard Greil,Panagiotis Samaras,

EClinicalMedicine (2023): 102318-102318

引用0浏览0WOS引用

Hodgkin Lymphoma—how Much Therapy Do We Need

Lehner Barbara,Panny Michael

memo - Magazine of European Medical Oncologyno. 1 (2022): 6-9

引用2浏览0引用

Comorbidities and Survival of DLBCL Patients (N=181) after First-line Therapy: The Score makes the Difference

F. Keil,M. Panny,A. Boehm, S. Burger,E. Koller,E. Menschel,T. Nosslinger,V. Rathkolb, M. Wilde, E. Zwettler,A. Krauter

ONCOLOGY RESEARCH AND TREATMENTno. SUPPL 2 (2022)

引用0浏览0引用

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Felix Keil,Antonia Maria Susanne Mueller,Andrea Berghold,Veronika Buxhofer-Ausch,Judith Schuster,Regina Riedl,Corinne Vorburger,Alexandra Boehm,Michael Panny,Thomas Noesslinger,Richard Greil,Panagiotis Samaras,

Blood（2022）

引用0浏览0引用

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth,Tea Pemovska,Gregory Vladimer,Gunther Bayer,Michael Bergmann,Sandra Eder,Ruth Eichner, Martin Erl,Harald Esterbauer,Ruth Exner,Verena Felsleitner-Hauer,Maurizio Forte,

CANCER DISCOVERY（2022）

引用56浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn